RASA1 — RAS p120 GTPase Activating Protein

RASA1 — RAS p120 GTPase Activating Protein

Overview

RASA1 (RAS p120 GTPase Activating Protein) is a critical regulator of RAS signaling pathways, functioning as a GTPase-activating protein (GAP) that accelerates the intrinsic GTP hydrolysis of RAS proteins. This converts active RAS-GTP to inactive RAS-GDP, serving as a key negative regulator of RAS-mediated signal transduction. RASA1 plays essential roles in vascular development, cell proliferation, and neuronal function.

<div class="infobox infobox-gene">
<table>
<tr><td><strong>Gene Symbol</strong></td><td>RASA1</td></tr>
<tr><td><strong>Full Name</strong></td><td>RAS p120 GTPase Activating Protein</td></tr>
<tr><td><strong>Chromosome</strong></td><td>5q14.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[10181](https://www.ncbi.nlm.nih.gov/gene/10181)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[139150](https://www.omim.org/entry/139150)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>[ENSG00000101577](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000101577)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P20156](https://www.uniprot.org/uniprot/P20156)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>RAS GTPase-activating proteins</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Capillary Malformation-AVM Syndrome, Parkes-Weber Syndrome, Neurodegeneration</td></tr>
</table>
</div>

Gene Structure and Expression

Genomic Organization

RASA1 — RAS p120 GTPase Activating Protein

Overview

RASA1 (RAS p120 GTPase Activating Protein) is a critical regulator of RAS signaling pathways, functioning as a GTPase-activating protein (GAP) that accelerates the intrinsic GTP hydrolysis of RAS proteins. This converts active RAS-GTP to inactive RAS-GDP, serving as a key negative regulator of RAS-mediated signal transduction. RASA1 plays essential roles in vascular development, cell proliferation, and neuronal function.

<div class="infobox infobox-gene">
<table>
<tr><td><strong>Gene Symbol</strong></td><td>RASA1</td></tr>
<tr><td><strong>Full Name</strong></td><td>RAS p120 GTPase Activating Protein</td></tr>
<tr><td><strong>Chromosome</strong></td><td>5q14.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[10181](https://www.ncbi.nlm.nih.gov/gene/10181)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[139150](https://www.omim.org/entry/139150)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>[ENSG00000101577](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000101577)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P20156](https://www.uniprot.org/uniprot/P20156)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>RAS GTPase-activating proteins</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Capillary Malformation-AVM Syndrome, Parkes-Weber Syndrome, Neurodegeneration</td></tr>
</table>
</div>

Gene Structure and Expression

Genomic Organization

The RASA1 gene spans approximately 140 kb on chromosome 5q14.1 and consists of 33 exons encoding a 1047-amino acid protein. The gene exhibits alternative splicing resulting in multiple isoforms with tissue-specific expression patterns.

Tissue Distribution

RASA1 exhibits broad expression:

• Vascular endothelium: High expression in endothelial cells lining blood vessels
• Brain: Expressed in neurons and glial cells, particularly in the hippocampus and cortex
• Heart and skeletal muscle: Moderate expression
• Kidney and liver: Present in epithelial cells
• Developing tissues: High expression during embryonic development

Mutation Spectrum and Pathogenic Variants

RASA1 harbors over 200 pathogenic variants associated with disease:

| Mutation Type | Percentage | Associated Phenotype |
|--------------|------------|---------------------|
| Nonsense/frameshift | ~45% | CM-AVM, Parkes-Weber |
| Missense | ~35% | CM-AVM, ASD |
| Splice site | ~15% | Variable penetrance |
| Large deletions | ~5% | Severe phenotypes |

Hotspot regions:

• Exons 4-8: C2 domain (phospholipid binding)
• Exons 17-22: GAP domain (catalytic activity)
• Exons 26-31: SH2 domain (protein interactions)

• Truncating mutations → more severe vascular phenotypes
• Missense in GAP domain → partial loss-of-function, neurodevelopmental features
• Splice variants → variable presentation

Protein Structure and Function

Molecular Architecture

The RASA1 protein contains several functional domains:

GAP Activity

RASA1 significantly accelerates RAS GTPase activity, increasing the rate of GTP hydrolysis by approximately 10,000-fold. This converts active RAS-GTP to inactive RAS-GDP, terminating RAS-mediated signaling.

Key Functions

RAS Signal Regulation

RASA1 negatively regulates multiple RAS effector pathways:

• RAF-MEK-ERK pathway: Controls cell proliferation and differentiation
• PI3K-AKT pathway: Regulates cell survival and metabolism
• RALGEF pathway: Modulates cytoskeletal dynamics

Vascular Development

RASA1 plays critical roles in angiogenesis and vascular patterning:

• Regulates endothelial cell proliferation and migration
• Controls vascular smooth muscle cell function
• Essential for proper arteriovenous differentiation

Neuronal Function

In neurons, RASA1 modulates:

• Synaptic plasticity and memory formation
• Neuronal differentiation and survival
• Response to growth factors

Disease Associations

Capillary Malformation-AVM Syndrome (CM-AVM)

CM-AVM is an autosomal dominant disorder caused by RASA1 mutations:

| Feature | Description |
|---------|-------------|
| Inheritance | Autosomal dominant |
| Prevalence | ~1 in 100,000 individuals |
| Core symptoms | Capillary malformations, arteriovenous malformations, AVM |
| Penetrance | Variable, approximately 90% |

Pathogenic Mechanisms

• Loss-of-function mutations: Lead to increased RAS-GTP levels
• Enhanced angiogenesis: Due to dysregulated RAS signaling
• Vascular abnormalities: Result from impaired endothelial function

Parkes-Weber Syndrome

A more severe form of vascular anomaly associated with RASA1:

• Multiple arteriovenous fistulas
• Tissue overgrowth
• High-flow vascular lesions

Neurodegenerative Implications

While primarily known for vascular disorders, RASA1 has been implicated in multiple neurological conditions:

RASA1 in Alzheimer's Disease Pathogenesis

The RAS-RAF-MEK-ERK pathway intersects with several key AD pathological mechanisms:

• Amyloid-beta signaling: RASA1 modulates the cellular response to amyloid-beta oligomers. In AD brains, RASA1 expression is downregulated in the hippocampus and prefrontal cortex, potentially contributing to dysregulated RAS signaling observed in AD neurons [1].
• Tau phosphorylation: The ERK pathway (downstream of RAS) can phosphorylate tau at multiple sites. RASA1 deficiency may therefore influence tau pathology through relieved inhibition of RAS-RAF-MEK-ERK signaling [2].
• Synaptic dysfunction: RAS GTPase activity is critical for synaptic plasticity. RASA1-mediated signal termination enables proper long-term potentiation (LTP) and memory consolidation. Impaired RASA1 function may contribute to synaptic failure in AD [3].

RASA1 in Parkinson's Disease

Dopaminergic neurons are particularly vulnerable to dysregulated RAS signaling:

• Neurotrophic factor signaling: RAS activation is required for signaling through neurotrophic receptors (BDNF, GDNF). RASA1 regulates the duration and intensity of these pro-survival signals [4].
• Mitochondrial function: RAS-PI3K-AKT signaling influences mitochondrial dynamics and survival. RASA1 loss may lead to excessive RAS activation and downstream pro-apoptotic signaling.
• Neuroinflammation: Microglial RASA1 modulates inflammatory responses. Dysregulation may contribute to chronic neuroinflammation in PD [5].

Neurodevelopmental Disorders

RASA1 mutations have been linked to:

• Autism spectrum disorder: RASA1 variants identified in ASD patients; affects neuronal connectivity
• Intellectual disability: Developmental delay associated with hypomorphic RASA1 alleles
• Epilepsy: Increased seizure susceptibility in RASA1-deficient models

Signaling Pathways

Therapeutic Approaches

Vascular Malformation Management

• Embolization: For AVM lesions
• Laser therapy: For capillary malformations
• mTOR inhibitors: Sirolimus for complex cases

Targeting RAS Signaling for Neurodegeneration

While direct RASA1-targeted therapies remain experimental, the RAS pathway offers multiple intervention points for neurodegenerative diseases:

MEK Inhibitors in Clinical Trials

• Trametinib (MEK1/2 inhibitor): Being investigated for RAS-associated neurodegeneration
• Selumetinib: Pediatric tumor studies inform neurological applications
• Cobimetinib: Shows promise in pre-clinical AD models

GAP Mimetics

Novel therapeutic approaches aim to restore RAS GAP activity:

• Small molecule GAP activators: Increase intrinsic GTPase activity
• Gene therapy: Deliver functional RASA1 to affected tissues
• Antisense oligonucleotides: Reduce mutant RASA1 expression

Combination Strategies

Rational combinations for neurodegeneration:

• MEK inhibitor + mTOR inhibitor: Dual pathway blockade
• RAS inhibitor + antioxidant: Address oxidative stress
• GAP activator + neurotrophic factor: Promote neuronal survival

RASA1 as Biomarker

RASA1 expression levels may serve as biomarkers:

• Diagnostic: RASA1 downregulation in AD hippocampus
• Prognostic: Correlation with disease severity
• Therapeutic monitoring: Response to RAS-targeted therapies

Interacting Partners

| Partner | Function | Reference |
|---------|----------|-----------|
| RAS proteins | Primary substrate | PMID: 8436416(https://pubmed.ncbi.nlm.nih.gov/8436416/) |
| p120-cas | Scaffold protein | PMID: 8621650(https://pubmed.ncbi.nlm.nih.gov/8621650/) |
| Grb2 | Adaptor protein | PMID: 8183535(https://pubmed.ncbi.nlm.nih.gov/8183535/) |
| p190RhoGAP | Rho GTPase regulation | PMID: 10831608(https://pubmed.ncbi.nlm.nih.gov/10831608/) |
| p130Cas | Tyrosine phosphorylation substrate | PMID: 7556138(https://pubmed.ncbi.nlm.nih.gov/7556138/) |
| Sprouty | Feedback inhibitor | PMID: 10918587(https://pubmed.ncbi.nlm.nih.gov/10918587/) |
| RAF1 | Kinase substrate | PMID: 1375858(https://pubmed.ncbi.nlm.nih.gov/1375858/) |

RAS Isoform Specificity

RASA1 exhibits differential activity toward RAS isoforms:

• HRAS: Highest GAP activity; RASA1 efficiently catalyzes GTP hydrolysis
• KRAS4A: Moderately recognized substrate
• KRAS4B: Less efficient interaction; alternative GAPs more important
• NRAS: Intermediate responsiveness

Animal Models

Mouse Models

• Rasa1 knockout: Embryonic lethal due to vascular defects
• Conditional knockout: Reveals tissue-specific functions
• Point mutants: Model human disease variants

Zebrafish Models

• rasa1 morphants: Demonstrate vascular abnormalities
• Used to study AVM formation

Key Publications

See Also

• [RAS Signaling Pathway](/mechanisms/ras-mapk-signaling)
• [Synaptic Plasticity](/mechanisms/synaptic-plasticity)
• [Cell Signaling](/mechanisms/cell-signaling)
• [Angiogenesis](/mechanisms/angiogenesis)
• [Capillary Malformation-AVM Syndrome](/diseases/capillary-malformation-avm)
• [Vascular Development](/mechanisms/vascular-development)

References

External Links

• [NCBI Gene: RASA1](https://www.ncbi.nlm.nih.gov/gene/10181)
• [OMIM: 139150](https://www.omim.org/entry/139150)
• [UniProt: P20156](https://www.uniprot.org/uniprot/P20156)
• [Ensembl: ENSG00000101577](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000101577)
• [Capillary Malformation Foundation](https://www.avmsociety.org/)

Pathway Diagram

The following diagram shows the key molecular relationships involving RASA1 — RAS p120 GTPase Activating Protein discovered through SciDEX knowledge graph analysis: